Primidone | 扑米酮 | NSC 41701 | Sodium Channel Inhibitor

首页 / / / / Primidone

普里米酮 /Primidone {[allProObj[0].p_purity_real_show]}

货号：A538446 同义名： 扑米酮;去氧苯比妥 / NSC 41701;NCI-C56360

Primidone is a pyrimidinedione derivative with anticonvulsant activity.

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Primidone 化学结构
CAS号：125-33-7

Primidone 3D分子结构
CAS号：125-33-7

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Primidone 纯度/质量文件产品仅供科研

货号：A538446 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell Host Microbe, 2024. Ambeed. [ A163338 ]; • Cancer Res., 2024. Ambeed. [ A295334 ]; • J. Pharm. Investig., 2024. Ambeed. [ A221527 , A691302 , A272538 , A187261 ]; • J. Fungi, 2024, 10(11): 751. Ambeed. [ A796919 ]; • JBC, 2024, 107935. Ambeed. [ A194396 ]; 更多 >

GABA受体亚型比较
钠通道亚型比较

产品名称	GABA receptor ↓ ↑	GABAA receptor ↓ ↑	其他靶点	纯度
Niflumic Acid	✔			98%
Ginkgolide A	++ GABA receptor, Ki: 14.5 μM			98%
Valproic acid sodium	✔		HDAC,Autophagy	97%
Flumazenil		✔		95%
Bemegride		✔		98%
Bicuculline		+++ GABAA receptor, IC50: 2 μM		98+%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	Sodium Channel ↓ ↑	纯度
Tolperisone HCl	✔	99%
Lamotrigine	✔	98%
Vinpocetine	✔	98%
Zonisamide	✔	98%
Dronedarone Hydrochloride	✔	95%
Procainamide hydrochloride	✔	99%
Bupivacaine HCl	✔	99+%
Benzocaine	✔	98%
Carbamazepine	++ Sodium channel, IC50: 131 μM	98%
Ibutilide fumarate	✔	99%+
Dibucaine HCl	✔	99+%
Mexiletine HCl	✔	99%
Phenytoin	✔	99+%
Camostat Mesylate	+++ epithelial sodium channel (ENaC), IC50: 50 nM	99%+
Levobupivacaine	✔	97+%
Oxcarbazepine	+ sodium channel, IC50: 160 μM	98%
Ambroxol		98+%
Primidone	✔	99%
Propafenone	✔	99%
A-803467	++++ Na(V1.8) channel, IC50: 8 nM	99%+
Rufinamide	✔	99%
Phenytoin sodium	✔	98%
Proparacaine Hydrochloride	+ Voltage-gated sodium channel, ED50: 3.4 mM	98+%
Riluzole	✔	97%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Primidone 生物活性

靶点

Sodium Channel

描述

Primidone is a minor first-generation antiepileptic drug, and also remains a first-line treatment of essential tremor. Although it is metabolized in phenyl-ethyl-malondamide and phenobarbital, active metabolites that contribute also to its action, primidone is not a prodrug and is active by itself. Generally accepted therapeutic range for primidone is between 5 and 10 mg/L (23-46 mmol/L)^[3]. Primidone, 50 to 1,000 mg/d, reduced the amplitude of essential tremor in both untreated and propranolol-treated patients. Low doses were as effective as high doses. Primidone decreased tremor more than propranolol. A single oral dose (250 mg) decreased tremor by 60% 1 to 7 hours after ingestion, with stable serum primidone levels. Tremor control was lost when phenobarbital was substituted for primidone shows primidone is an effective agent for the treatment of essential tremor^[4].

Primidone 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01771523	Goiter	Not Applicable	Completed	-	Turkey ... 展开 >> Maltepe University School of Medicine, General Surgery Department İstanbul, Turkey, 34843 收起 <<
NCT01816568	Acute Appendicitis	Not Applicable	Completed	-	-
NCT01772745	Gallbladder Disease	Not Applicable	Completed	-	-

Primidone 参考文献

[1]Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia. 1995;36 Suppl 2:S2-12.

[2]Calzetti S, Findley LJ, et al. Phenylethylmalonamide in essential tremor. A double-blind controlled study. J Neurol Neurosurg Psychiatry. 1981 Oct;44(10):932-4.

[3]Bentué-Ferrer D, Verdier MC, Tribut O. Suivi thérapeutique pharmacologique de la primidone et du phénobarbital [Therapeutic drug monitoring of primidone and phenobarbital]. Therapie. 2012 Jul-Aug;67(4):381-90. French.

[4]Koller WC, Royse VL. Efficacy of primidone in essential tremor. Neurology. 1986 Jan;36(1):121-4.

Primidone 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

4.58mL

0.92mL

0.46mL

22.91mL

4.58mL

2.29mL

45.82mL

9.16mL

4.58mL

Primidone 技术信息

CAS号	125-33-7
分子式	C₁₂H₁₄N₂O₂
分子量	218.252

别名	扑米酮;去氧苯比妥;扑痫酮;密苏林;美速林 ;NSC 41701;NCI-C56360;XcelBrand of Primidone;Sertan;Sanofi-Synthelabo Brand of Primidone;Resimatil;Mysoline;Mizodin;Mylepsinum;Primaclone
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,Room Temperature

溶解度

DMSO: 50 mg/mL(229.09 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01771523	Goiter	Not Applicable	Completed	-	Turkey ... 展开 >> Maltepe University School of Medicine, General Surgery Department İstanbul, Turkey, 34843 收起 <<
NCT01816568	Acute Appendicitis	Not Applicable	Completed	-	-
NCT01772745	Gallbladder Disease	Not Applicable	Completed	-	-
NCT00903786	Refractory Partial Seizures	Phase 2	Completed	-	Japan ... 展开 >> Kitakyusyu, Fukuoka, Japan Kobe, Hyogo, Japan Sendai, Miyagi, Japan Komatsushima, Tokushima, Japan Kodaira, Tokyo, Japan Kyoto, Japan Nagasaki, Japan Niigata, Japan Shizuoka, Japan 收起 <<
NCT00903786	-		Completed	-	-
NCT00404248	Brain and Central Nervous Syst... 展开 >>em Tumors 收起 <<	Phase 1 Phase 2	Completed	-	United States, Alabama ... 展开 >> UAB Comprehensive Cancer Center Birmingham, Alabama, United States, 35294-3410 United States, Florida H. Lee Moffitt Cancer Center and Research Institute at University of South Florida Tampa, Florida, United States, 33612-9497 United States, Georgia Winship Cancer Institute of Emory University Atlanta, Georgia, United States, 30322 United States, Maryland Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21231 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 United States, Michigan Josephine Ford Cancer Center at Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, North Carolina Wake Forest University Comprehensive Cancer Center Winston-Salem, North Carolina, United States, 27157-1096 United States, Ohio Cleveland Clinic Taussig Cancer Center Cleveland, Ohio, United States, 44195 United States, Pennsylvania Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104-4283 收起 <<
NCT00068770	Brain and Central Nervous Syst... 展开 >>em Tumors 收起 <<	Phase 2	Terminated(EORTC trail showed ... 展开 >>TMZ & RT conferred significant survivial in this population) 收起 <<	-	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612-9497 United States, Georgia Winship Cancer Institute of Emory University Atlanta, Georgia, United States, 30322 United States, Maryland Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21231-2410 United States, Massachusetts Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114-2617 United States, North Carolina Comprehensive Cancer Center at Wake Forest University Winston-Salem, North Carolina, United States, 27157-1030 United States, Ohio Cleveland Clinic Taussig Cancer Center Cleveland, Ohio, United States, 44195 United States, Pennsylvania Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104-4283 收起 <<
NCT00102596	Essential Tremor	Phase 2	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT00102596	-		Completed	-	-
NCT00404248	-		Completed	-	-
NCT00068770	-		Terminated(EORTC trail showed ... 展开 >>TMZ & RT conferred significant survivial in this population) 收起 <<	-	-
NCT01018485	Multiple Sclerosis ... 展开 >> Tremor 收起 <<	Phase 3	Completed	-	Australia, Victoria ... 展开 >> Melbourne Health Melbourne, Victoria, Australia, 3050 收起 <<
NCT02555982	Essential Head Tremor	Phase 3	Unknown	December 2017	France ... 展开 >> CHU de Clermont-Ferrand Recruiting Clermont-Ferrand, France, 63003 Contact: Patrick LACARIN 04 73 75 11 95 placarin@chu-clermontferrand.fr Principal Investigator: Franck DURIF 收起 <<
NCT00734864	Glioblastoma Multiforme ... 展开 >> Gliosarcoma Anaplastic Astrocytoma Anaplastic Oligodendroglioma Glioma 收起 <<	Phase 1	Withdrawn(Study drug supplier ... 展开 >>withdrew support for the study. Study was withdrawn from the Duke IRB.) 收起 <<	June 2012	United States, North Carolina ... 展开 >> Duke University Medical Center Durham, North Carolina, United States, 27710 收起 <<
NCT01390909	-		Completed	-	-
NCT02827955	Patients With Parkinson's Dise... 展开 >>ase 收起 <<	Not Applicable	Unknown	April 2018	France ... 展开 >> Assistance Publique Hôpitaux de Marseille Recruiting Marseille, France, 13354 Contact: Jean REGIS, PUPH 0491387058 jregis@ap-hm.fr Principal Investigator: Jean REGIS, PUPH 收起 <<
NCT03101241	Essential Tremor	Phase 2	Completed	-	-
NCT00685165	-		Completed	-	-
NCT01390909	-		Completed	-	-
NCT01132040	Healthy	Phase 1	Completed	-	India ... 展开 >> Bioserve Clinical Research Pvt. Ltd, HYD, Andhra Pradesh, India, 500 037 收起 <<
NCT00685165	Therapeutic Equivalency	Phase 1	Completed	-	-
NCT02008123	Clopidogrel Resistance ... 展开 >> Secondary Stroke Prevention 收起 <<	Phase 2	Withdrawn(Inclusion/Exclusion ... 展开 >>criteria was too stringent to enroll patients at this site.) 收起 <<	-	United States, New York ... 展开 >> Dent Neurologic Institute Amherst, New York, United States, 14226 收起 <<

普里米酮 /Primidone {[allProObj[0].p_purity_real_show]}

Primidone 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Primidone 质控信息

Primidone 生物活性

Primidone 临床研究

Primidone 参考文献

Primidone 实验方案

Primidone 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

普里米酮 /Primidone {[allProObj[0].p_purity_real_show]}

Primidone 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Primidone 质控信息

Primidone 生物活性

Primidone 临床研究

Primidone 参考文献

Primidone 实验方案

Primidone 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Primidone 纯度/质量文件产品仅供科研